The Respironics division at Philips (NYSE:PHG) yesterday released the Patient Adherence Management Services designed to support new patients transitioning into continuous positive airway pressure sleep therapy. The company claims the service can boost sleep patient adherence by16% over the first 30 days of therapy, up to 24% within the first 90 days and an average of 49% […]
Philips Respironics settles kickbacks case for $35m
The Respironics division at Philips (NYSE:PHG) agreed to pay $34.8 million to settle U.S. Justice Dept. claims that it paid kickbacks in the form of free call center services to induce suppliers into buying its sleep apnea masks. Today’s settlement resolves a whistleblower lawsuit filed by South Carolina pharmacist Dr. Gibran Ameer, who worked for medical equipment suppliers that bought […]
Philips Respironics Esprit ventilator recall is Class I
Philips’ ventilator recall gets FDA’s highest-risk status | MassDevice.com On Call
MASSDEVICE ON CALL — Philips Healthcare (NYSE:PHG) subsidiary Respironics got the FDA’s highest-level warning over a recall of certain Trilogy ventilators.
Philips Healthcare’s Respironics pulls more ventilators
Recall: FDA puts highest-risk label on Respironics’ V60 ventilators
Recall: Respironics pulls more ventilators
Philips Healthcare (NYSE:PHG) subsidiary Respironics Inc. announced a new recall affecting a set of its V60 ventilators after the company received reports of 2 motor failures.
Respironics has already informed all of its U.S. customers and has updated 33 of the 116 affected units with new blowers, according to a press release.
Recall: Philips’ Respironics ventilator gets Class I status
The FDA slapped Philips Healthcare (NYSE:PHG) subsidiary Respironics Inc. with a Class I recall for manufacturing issues in its ventilators that the agency says may result in patient injury or death.
Certain of the company’s Trilogy 100 ventilators may stop circulating air if a blower component moves out of place. The devices are rigged to sound an alarm in such an event, but delayed attention could result in serious harm to a patient, according to the FDA.